A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Active, not recruiting · Phase 2, Phase 3 · NCT07076121
Conditions: Pancreatic Ductal Adenocarcinoma
At a glance
- Research payments reported, 2025
- $2,762
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 470
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Navlimetostat (drug), Gemcitabine (drug), Nab-paclitaxel (drug), Placebo (drug)
- Dates
- Started 2025-10-23; completion 2029-05-03
- Results posted
- Not yet
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
From ClinicalTrials.gov, last updated 2026-06-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $2,762 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Walid L. Shaib, M.D. Hematology & Oncology · New Haven, CT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwest Georgia Oncology Centers, PC $1,686
- Highlands Oncology Group $1,075
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.